Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
Many new drugs on the market are chiral compounds, that is, they can exist in two non-superimposable mirror-image forms. Asymmetric catalysis encompasses a large variety of processes for obtaining such compounds.
Many new drugs on the market are chiral compounds, that is, they can exist in two non-superimposable mirror-image forms. Asymmetric catalysis encompasses a large variety of processes for obtaining such compounds.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Montserrat Diéguez studied chemistry at the Rovira i Virgili University (URV) in Tarragona (Spain), where she earned her Ph.D. in 1997, working in the group of Prof. C. Claver. After completing a postdoctoral fellowship where she worked with Prof. R.H. Crabtree at Yale University, in New Haven (USA), she returned to Tarragona in 1999 and accepted a lectureship position at the URV, becoming part of the permanent staff in 2002. In 2011 she was promoted to full Professor in Inorganic Chemistry at the URV. She has been involved in more than 60 research projects in the fields of organometallic chemistry, steroselective synthesis, and asymmetric catalysis. She is the author/co-author of more than 150 articles in SCI-indexed journals and book chapters, and of several contributions to conferences. She received distinction from the Generalitat de Catalunya for the promotion of University Research in 2004 and from the URV in 2008. She has also been awarded the ICREA Academia Prize from the Catalan Institution for Research and Advanced Studies 2009-14 and 2015-20, for research excellence, facilitating research priority dedication. Her main research interests are focused on the sustainable design, synthesis, and screening of highly active and selective chiral catalysts for reactions of interest to the biological, pharmaceutical, and organic nanotechnological industries. Her areas of interest include organometallic chemistry, stereoselective synthesis, and asymmetric catalysis, using combinatorial and biotechnological approaches.
Inhaltsangabe
Contents Preface......................................................................................................................vii Editor.........................................................................................................................ix List of Contributors....................................................................................................xi Abbreviations and Acronyms................................................................................. xiii Chapter 1 Chiral Bidentate Heterodonor P-Oxazoline Ligands ...........................1 Maria Biosca, Jordi Faiges, Montserrat Diéguez, and Oscar Pàmies Chapter 2 Chiral Bidentate Heterodonor P-N -Other-Ligands............................. 33 Pep Rojo, Marina Bellido, Xavier Verdaguer, and Antoni Riera Chapter 3 Chiral Bidentate Heterodonor P,S/O Ligands..................................... 81 Jèssica Margalef and Miquel A. Pericàs Chapter 4 Chiral Bidentate Heterodonor P-P' ligands....................................... 109 Antonio Pizzano Chapter 5 Chiral Tridentate-Based Ligands...................................................... 167 Uchchhal Bandyopadhyay, Basker Sundararaju, Rinaldo Poli, and Eric Manoury Chapter 6 Chiral N-Heterocyclic Carbene-Based Ligands................................ 195 Vincent César, Christophe Fliedel, and Agnès Labande Chapter 7 Chiral Monophosphorus Ligands...................................................... 233 Wenjun Tang, Feng Wan, and He Yang Chapter 8 Solvent-Oriented Ligand and Catalyst Design in Asymmetric Catalysis - Principles and Limits ..................................................... 261 Armin Börner Index....................................................................................................................... 315
